NCT05269316
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease; Patients with any treatment targeting the ATR/CHK1 pathway
https://ClinicalTrials.gov/show/NCT05269316